Protect established revenue
Review retention, access and continuity for the two largest products, and stress-test concentration.
Life sciences strategy
Balancing portfolio concentration with selective growth
Portfolio, channel and adoption analysis to distinguish established value from growth hypotheses.
71.2%Top-two product sales share
15.5%Reported sales growth
92.5%Net growth from the top two
The decision behind the data.
Where should commercial resources protect established revenue, test growth opportunities or wait for stronger evidence?
An anonymised global pharmaceutical company
Two products carried most of the reported value
We reconciled reported sales and unit totals, measured concentration and growth contribution, and compared channels and markets. A separate emerging-therapy adoption scenario examined the distinction between growth rate and commercial scale.
Product A / 37.6%Product B / 33.6%Other five / 28.8%
What the analysis showed.
The two largest coded products accounted for 71.2% of 2024 reported sales and 92.5% of net sales growth in 2016–24. Reported sales grew 15.5% and units 18.5%. Retail represented 59.7% of reported sales; sales mix alone does not establish channel profitability.
Reported growth in 2016–24. Comparable unit definitions, price, mix, currency and coverage need validation before attributing the difference.
Market A: 83.0% of sales, but 8.6% of units
Reconcile unit definitions, sales basis, currency and coverage before ranking markets for investment. The mismatch is not a proven pricing advantage.
Adoption: growth rate is not scale
| Coded therapy | 2019–24 unit CAGR | 2024 unit share |
|---|---|---|
| A | 26.4% | 75.8% |
| B | 24.1% | 21.8% |
| C | 43.7% | 2.4% |
The source identifies the adoption series as hypothetical. Shares cover the three coded therapies, not all treatments or patients. Pricing inputs are missing, so units do not establish revenue or returns.
A clear route to the next decision.
Test selective growth
Validate volume momentum, net price and contribution before bounded commercial pilots.
Validate market economics
Reconcile units, sales basis, currency and coverage; obtain missing price and margin inputs.
Govern the next decision
Use the proposed 90-day plan to validate, prioritise and pilot before reallocating resources.
Proposed 90-day delivery plan
- Days 0–30
Validate and baseline
Commercial factbook and agreed definitions.
- Days 31–60
Prioritise and design
Ranked opportunities and pilot charters.
- Days 61–90
Pilot and review
Pilot read-outs and scale, adjust or stop decisions.
What the work delivered.
- Portfolio diagnosis
- Concentration, growth contribution, volume trends, channel mix and market-data checks.
- Strategic recommendation
- Protect the core, test growth options and validate the economics before reallocation.
- Execution roadmap
- A proposed 90-day sequence with owners, outputs and commercial KPI reviews.
Analytical work and recommendations. The 90-day plan is proposed; implementation, revenue uplift and return on investment are not evidenced.
Read the complete case study PDF